News:Less Than One Month Remaining until the Submission Deadline for Phase 1 of the NCTR Indel Calling from Oncopanel Sequencing Data Challenge!
1
0
Entering edit mode
2.4 years ago
sarah_p ▴ 10

Reminder! We are less than one month out from the NCTR Indel Calling from Oncopanel Sequencing Data Challenge submission deadline! There’s still time to join the challenge.

This challenge is being hosted in collaboration with the FDA’s National Center for Toxicological Research (NCTR) and is taking part in two phases.

Phase 1 of the challenge will run through July 8th and Phase 2 will run from July 11th-July 26th.

The primary goal of this challenge is to encourage the bioinformatics community to develop, validate, and benchmark indel calling pipelines to identify indels in oncopanel sequencing datasets. Given the widely recognized impact of indels on protein coding and function, it is crucial that the tools for indel-calling be rigorously evaluated and optimized.

Winners of the challenge will be publicly recognized and invited to contribute to a manuscript and a webinar describing the challenge and their submission results. Visit the challenge site below to get started or to submit your results!

https://go.usa.gov/xJwKS

oncopanel indel-calling • 1.4k views
ADD COMMENT
0
Entering edit mode

How does one get manually recognized? Or is that annually?

ADD REPLY
0
Entering edit mode

Hi Mensur! Winners of the challenge will be publicly recognized by the FDA.

ADD REPLY
0
Entering edit mode
2.4 years ago
sarah_p ▴ 10

There are only a few days left to submit your results for the NCTR Indel Calling from Oncopanel Sequencing Data Challenge! Phase 1 closes on July 8th. Those who completed Phase 1 for both Oncopanel A & Oncopanel B will be able to participate in the optional Phase 2 that runs from July 11th-July 26th.

Visit the site below to submit your final results! https://go.usa.gov/xJzdv

ADD COMMENT

Login before adding your answer.

Traffic: 882 users visited in the last hour
Help About
FAQ
Access RSS
API
Stats

Use of this site constitutes acceptance of our User Agreement and Privacy Policy.

Powered by the version 2.3.6